7 Best Peptides for Anti-Aging, Ranked

Aging is not a single process. It is at least twelve interconnected mechanisms — telomere shortening, mitochondrial dysfunction, cellular senescence, epigenetic drift, and others — all degrading tissue function simultaneously. The 2023 update to the hallmarks of aging framework identified twelve distinct drivers, each a potential therapeutic target (Lopez-Otin et al., 2023).

This is where peptides offer something most anti-aging interventions do not: specificity. Rather than broadly "supporting health," individual peptides target discrete hallmarks. Epitalon activates telomerase. FOXO4-DRI clears senescent cells. SS-31 stabilizes the inner mitochondrial membrane. Each addresses a different root cause of biological aging.

This article ranks seven peptides with the strongest anti-aging evidence, explains which hallmark each targets, and provides a framework for choosing the right one — or combining several — based on your goals.

Anti-Aging Peptide Comparison

1. Epitalon — Telomere Maintenance

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from epithalamin, a pineal gland extract studied extensively by Russian gerontologist Vladimir Khavinson. Its primary anti-aging mechanism is telomerase activation. In a 2003 study, adding epitalon to human fibroblast cultures induced telomerase activity and caused measurable telomere elongation in cells that were previously telomerase-negative (Khavinson et al., 2003).

The longevity data in animals is notable. Animal studies suggest epitalon extends maximum lifespan by 12-13% and reduces spontaneous tumor incidence. Beyond telomeres, epitalon restores pineal melatonin synthesis in aged organisms. This matters more than most people realize: melatonin is not merely a sleep hormone but a potent mitochondrial antioxidant, immune modulator, and epigenetic regulator. With age, the pineal gland calcifies and melatonin output drops by 50-80% by age 60. This decline disrupts circadian signaling across every tissue. Chronic circadian disruption accelerates multiple hallmarks simultaneously — inflammatory gene expression increases, DNA repair efficiency drops during overnight repair windows, and metabolic hormones lose their diurnal rhythm. By restoring endogenous melatonin production at the source, epitalon addresses circadian aging upstream rather than relying on exogenous melatonin supplementation, which does not restore the natural secretion pattern.

The practical advantage of epitalon is its cycling protocol. Standard protocols run 10-20 days at 5-10 mg subcutaneously per day, administered once daily in the evening to align with natural pineal activity. Cycles are repeated every 4-6 months. Some practitioners use a loading approach of 10 days at 10 mg for the first cycle, then maintenance cycles of 20 days at 5 mg. The rest period between cycles reflects the observation that telomerase activation and pineal restoration persist for months after the active dosing window — continuous administration does not appear to produce proportionally greater effects. This makes epitalon one of the least burdensome anti-aging peptides in terms of ongoing commitment. The main limitation is the absence of human longevity trials — the evidence base is strong for mechanism but relies on animal and cell models for lifespan outcomes.

Best for: Those prioritizing telomere health and circadian rhythm restoration. Pairs well with NAD+ support.

2. SS-31 (Elamipretide) — Mitochondrial Rescue

SS-31 is the most clinically advanced peptide on this list. It targets the inner mitochondrial membrane by binding cardiolipin, a phospholipid essential for electron transport chain efficiency. When cardiolipin becomes oxidized with age, ATP production drops and reactive oxygen species increase. SS-31 stabilizes cardiolipin structure and restores normal mitochondrial bioenergetics (Birk et al., 2013).

The aging data is compelling. In old mice (24 months), just 8 weeks of SS-31 treatment reversed age-related diastolic cardiac dysfunction, normalized mitochondrial proton leak, and reduced protein oxidation in heart tissue (Siegel et al., 2020). This was not prevention — it was reversal of pre-existing cardiac aging.

SS-31 has completed multiple human clinical trials under its pharmaceutical name elamipretide, including studies in heart failure and primary mitochondrial myopathy. Its strongest regulatory milestone came from Barth syndrome trials — a rare genetic disorder where defective cardiolipin remodeling causes severe cardiomyopathy. In these patients, elamipretide improved six-minute walk distance, cardiac stroke volume, and patient-reported quality of life, leading to FDA Breakthrough Therapy designation. While Barth syndrome is a rare disease, the trial results validated the core mechanism: stabilizing cardiolipin improves mitochondrial function in living humans, not just cell cultures or mouse models.

An important distinction: pharmaceutical elamipretide and research-grade SS-31 share the same amino acid sequence (D-Arg-Dmt-Lys-Phe-NH2) but differ in manufacturing standards. Research-grade SS-31 from peptide vendors has not undergone pharmaceutical-grade quality control — this does not necessarily mean lower purity, but third-party certificate of analysis verification is essential.

Best for: Those with mitochondrial concerns — fatigue, cardiac aging, exercise intolerance. The strongest clinical evidence of any peptide on this list.

3. MOTS-c — Metabolic Aging

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA — one of only a handful of known mitochondrial-derived peptides. Discovered in 2015 by Changhan Lee's lab, MOTS-c regulates glucose metabolism, insulin sensitivity, and fatty acid oxidation through the AMPK pathway (Lee et al., 2015).

What makes MOTS-c relevant to aging specifically is its role as an exercise mimetic. Circulating MOTS-c levels decline with age, and supplementation in aged mice restores metabolic parameters to younger levels. It activates AMPK — the same energy-sensing pathway triggered by exercise and caloric restriction — positioning it as a pharmacological bridge for those who cannot maintain high physical activity levels.

MOTS-c also translocates to the nucleus during metabolic stress, directly regulating gene expression related to stress adaptation. This nuclear translocation is a defining feature: under metabolic challenge (glucose deprivation, folate stress, exercise), MOTS-c physically moves from cytoplasm into the nucleus where it interacts with antioxidant response element (ARE) transcription factors, activating protective gene programs. MOTS-c thus functions as a retrograde signal from mitochondria to the nuclear genome — a communication pathway that degrades with age. Human correlational data supports this: circulating MOTS-c levels are significantly higher in physically active individuals compared to sedentary controls, and decline predictably with age. In centenarian populations, MOTS-c levels remain elevated compared to age-matched controls, suggesting maintained MOTS-c signaling may be both a biomarker and driver of successful metabolic aging.

Best for: Metabolic aging, insulin resistance, and those seeking exercise-mimetic benefits. Complementary to SS-31 (different mitochondrial targets).

4. NAD+ (and Precursors NMN/NR) — Sirtuin Activation

NAD+ is not a peptide in the traditional sense, but it is central to every serious anti-aging protocol and acts through peptide-like signaling cascades. NAD+ levels decline by approximately 50% between ages 40 and 60, directly impairing sirtuin function, DNA repair capacity, and mitochondrial communication (Imai & Guarente, 2014).

The mechanism is well-characterized. Declining NAD+ creates a pseudohypoxic state that disrupts nuclear-mitochondrial signaling, accelerating age-related metabolic dysfunction. Restoring NAD+ through precursors like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) reactivates sirtuins — a family of enzymes that regulate DNA repair, inflammation, and mitochondrial biogenesis.

Human trials with NMN and NR have demonstrated increased blood NAD+ levels, improved insulin sensitivity, and enhanced muscle function in older adults. NAD+ can also be delivered via IV infusion for faster repletion. The oral precursor route (NMN/NR) offers the lowest barrier to entry of any intervention on this list — no injection required.

Best for: Foundational anti-aging support. Works synergistically with nearly every other peptide on this list by ensuring adequate cellular NAD+ for sirtuin-dependent repair processes.

5. Humanin — Cytoprotection and Neuroprotection

Humanin is a 24-amino-acid peptide encoded in mitochondrial DNA, discovered through its ability to protect neurons against amyloid-beta toxicity. It has since been shown to regulate lifespan and healthspan across multiple model organisms.

The aging connection runs deep. Circulating humanin levels decline with age in humans, and higher humanin levels correlate with better cognitive performance and lower Alzheimer's risk. In mice, humanin administration prevented age-related cognitive decline, and human studies found that circulating humanin levels are associated with improved cognitive age.

Beyond neuroprotection, humanin acts as a broad cytoprotective agent. It inhibits apoptosis by preventing Bax-mediated mitochondrial membrane permeabilization, protects against oxidative stress, and modulates inflammatory signaling through the STAT3 and ERK1/2 pathways. One key interaction is with IGFBP-3 (insulin-like growth factor binding protein-3). IGFBP-3 normally promotes apoptosis, but humanin binds it and blocks this pro-apoptotic signaling — creating a survival advantage in stressed cells. This links humanin to the GH/IGF-1 axis, one of the most established longevity pathways. Animal dose-response studies show that humanin analogs (particularly the S14G mutant, HNG, roughly 1,000-fold more potent than native humanin) produce protective effects across a wide range — from low nanomolar concentrations for neuroprotection to higher doses for systemic metabolic benefits. The dose-response curve is relatively forgiving compared to peptides with narrow therapeutic windows, though optimal human dosing remains an active research question.

Best for: Neuroprotective aging strategies, cognitive preservation, and broad cytoprotection. Particularly relevant for those with family history of neurodegenerative disease.

6. FOXO4-DRI — Senescent Cell Clearance

Cellular senescence — the accumulation of "zombie cells" that stop dividing but refuse to die — is one of the most actionable hallmarks of aging. Senescent cells secrete inflammatory molecules (the senescence-associated secretory phenotype, or SASP) that damage surrounding tissue and accelerate aging in neighboring cells.

FOXO4-DRI is a D-retro-inverso peptide that disrupts the FOXO4-p53 interaction keeping senescent cells alive. The "D-retro-inverso" design is notable peptide engineering: the peptide is synthesized using D-amino acids (mirror images of natural L-amino acids) in reversed sequence order. This inversion preserves the side-chain topology needed to bind FOXO4 while making the peptide invisible to proteases that would rapidly degrade a normal L-amino acid peptide. The result is dramatically improved metabolic stability and a longer biological half-life — critical for a peptide that must penetrate cells and reach nuclear foci where FOXO4-p53 complexes reside.

In normal senescent cells, FOXO4 sequesters p53 in promyelocytic leukemia (PML) nuclear bodies, preventing p53 from triggering apoptosis. FOXO4-DRI competitively disrupts this interaction, releasing p53 to selectively induce cell death in senescent cells while leaving healthy cells unaffected (Baar et al., 2017).

In aged mice, FOXO4-DRI treatment restored fur density, improved renal function, and enhanced overall fitness. The selectivity is the key advantage — unlike broad-spectrum senolytics (dasatinib + quercetin), FOXO4-DRI targets a specific molecular interaction unique to the senescent state. For those considering FOXO4-DRI, measuring senescent cell burden before and during treatment provides objective feedback. The most established biomarkers include p16INK4a expression (a cyclin-dependent kinase inhibitor that accumulates specifically in senescent cells), SA-beta-galactosidase activity (detectable in tissue samples), and circulating SASP factors like IL-6, MCP-1, and PAI-1. While p16INK4a measurement currently requires tissue biopsy or specialized blood assays, circulating inflammatory markers (hsCRP, IL-6) serve as practical surrogate endpoints accessible through standard lab panels. The main limitation of FOXO4-DRI is cost and limited human data; this remains one of the more experimental entries on this list.

Best for: Those specifically targeting cellular senescence and SASP-driven inflammation. Best approached after addressing foundational hallmarks (mitochondria, NAD+, telomeres).

7. GHK-Cu — Epigenetic Reset and Tissue Repair

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide found in human plasma, with levels declining from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. While often categorized as a skin and wound healing peptide, its anti-aging data goes far deeper than cosmetics.

Gene expression studies revealed that GHK-Cu modulates over 4,000 human genes — roughly 6% of the genome. It upregulates genes associated with DNA repair, antioxidant defense, and stem cell activity while downregulating genes linked to inflammation, tissue destruction, and cancer metastasis (Pickart et al., 2018). This broad gene-resetting capacity positions GHK-Cu as an epigenetic modulator rather than a narrow-target peptide.

GHK-Cu also has demonstrated effects on cognitive-relevant pathways. It suppresses genes involved in oxidative stress and neurodegeneration while promoting expression of nerve growth factors and antioxidant enzymes. Its availability in both injectable and topical forms makes it one of the most accessible anti-aging peptides.

Best for: Those wanting broad epigenetic support with visible skin benefits. Available topically (lowest barrier) or injectable (systemic effects). Strong safety record.

Stacking Approaches

Because each peptide targets a different hallmark, multi-peptide anti-aging strategies are logical. Here are three evidence-informed stacking frameworks.

Foundation Stack (Beginner)

• NAD+ precursor (NMN 500-1000 mg/day oral) — metabolic foundation
• GHK-Cu (topical daily or injectable 1-2x/week) — epigenetic support with visible skin benefits
• Epitalon (5-10 mg/day for 10-20 days, every 4-6 months) — telomere maintenance

This stack covers three distinct hallmarks with minimal injection burden and well-established safety profiles.

Mitochondrial Stack (Intermediate)

• SS-31 — inner membrane cardiolipin protection
• MOTS-c — AMPK-mediated metabolic regulation
• NAD+ — sirtuin activation and mitochondrial communication

These three peptides address mitochondrial aging from different angles: membrane integrity (SS-31), metabolic signaling (MOTS-c), and cofactor availability (NAD+).

Comprehensive Stack (Advanced)

• Epitalon (cycled) — telomeres
• SS-31 or MOTS-c — mitochondria
• NAD+ — sirtuins/DNA repair
• FOXO4-DRI (cycled) — senescent cell clearance
• GHK-Cu — epigenetic modulation

This addresses five hallmarks simultaneously. Introduce one peptide at a time over 4-8 weeks to isolate any side effects. Bloodwork monitoring is essential at this level — track inflammatory markers (hsCRP, IL-6), metabolic panels, and liver enzymes.

Monitoring and Bloodwork

Any multi-peptide anti-aging protocol demands structured bloodwork — both to establish a pre-protocol baseline and to objectively track whether interventions are moving the needle. The most immediately relevant panel focuses on inflammatory markers. High-sensitivity C-reactive protein (hsCRP) captures systemic inflammation and is the single best proxy for SASP-driven tissue damage from senescent cells. Interleukin-6 (IL-6) adds resolution: it is a primary SASP cytokine, directly downstream of the senescent cell burden that FOXO4-DRI targets. If you are running a senolytic protocol, a meaningful drop in IL-6 within 8-12 weeks is one of the earliest confirmations that clearance is occurring. TNF-alpha rounds out the inflammatory triad and is particularly relevant for those stacking GHK-Cu, given its broad suppression of pro-inflammatory gene networks.

A comprehensive metabolic panel provides the structural context that inflammatory markers alone cannot. Fasting glucose, insulin, and HOMA-IR quantify metabolic aging directly — these are the endpoints MOTS-c and NAD+ precursors are designed to improve. Liver enzymes (ALT, AST, GGT) serve double duty: they flag hepatic stress from any injectable protocol and track the liver's own aging trajectory, since hepatic NAD+ depletion is one of the earliest organ-specific manifestations of metabolic aging. A lipid panel with ApoB, a complete metabolic panel, and kidney function markers (BUN, creatinine, eGFR) complete the picture. Run this panel at baseline, then quarterly for the first year. Deviations from your personal baseline matter more than population reference ranges.

For those investing in longer-horizon biomarkers, telomere length testing and mitochondrial function markers add a layer of specificity that standard bloodwork cannot provide. Telomere length — measured via qPCR or the more precise Flow-FISH method — is the primary objective endpoint for epitalon users. A single measurement has limited utility; the value emerges from serial testing every 6-12 months to track attrition rate rather than absolute length. Mitochondrial markers are harder to access but increasingly available: lactate-to-pyruvate ratio reflects electron transport chain efficiency (relevant for SS-31 users), while whole-blood NAD+ levels confirm whether NMN or NR supplementation is actually reaching cellular targets. CoQ10 levels and organic acid profiles (urinary methylmalonic acid, ethylmalonic acid) provide additional mitochondrial resolution. Pair these specialized tests with an epigenetic age clock (GrimAge or DunedinPACE) at baseline and annually — the combination of inflammatory, metabolic, telomere, and epigenetic data creates a multi-dimensional aging dashboard that no single marker can replicate.

How to Choose

Selecting anti-aging peptides depends on three factors:

1. Which hallmark matters most to you? If family history includes neurodegenerative disease, humanin and NAD+ take priority. If you have metabolic syndrome or insulin resistance, MOTS-c and NAD+ are the foundation. If you are focused on cellular aging biomarkers, epitalon and FOXO4-DRI target the measurable endpoints (telomere length, senescent cell burden).

2. Evidence threshold. If you only want compounds with human clinical trial data, SS-31 and NAD+ precursors are the strongest options. If you are comfortable with strong animal data and mechanistic evidence, epitalon, MOTS-c, and humanin expand your toolkit significantly.

3. Practical constraints. NAD+ precursors and GHK-Cu (topical) require no injections. Epitalon's short cycling protocol (10-20 days, twice yearly) minimizes injection burden. SS-31, MOTS-c, humanin, and FOXO4-DRI require regular subcutaneous injections during active use.

4. Measurability. Longevity outcomes take decades to manifest, making surrogate biomarkers essential. Before starting any protocol, establish baselines: epigenetic age clocks (GrimAge, TruAge) for composite biological age, telomere length testing for epitalon users, inflammatory markers (hsCRP, IL-6) for senolytic approaches, and NAD+ blood levels for NMN/NR protocols. Tracking two or three relevant markers across 6-12 month intervals creates an evidence base for protocol decisions. See the Measuring Anti-Aging Progress section below for specific testing strategies.

Measuring Anti-Aging Progress

The fundamental challenge with anti-aging interventions is the timescale: you cannot wait 30 years to determine whether a protocol worked. Surrogate biomarkers — measurable indicators that correlate with biological aging rate — provide interim feedback. No single test is definitive, but a panel approach gives actionable data.

Epigenetic clocks are the most validated biological age measurement. These algorithms analyze DNA methylation patterns at specific CpG sites to estimate biological age independent of chronological age. Second-generation clocks like GrimAge and DunedinPACE go further — GrimAge predicts time-to-death and disease onset, while DunedinPACE measures the current pace of aging (how fast you are aging now, not just how aged you are). Commercial tests (TruAge, myDNAge) make this accessible through mail-in blood spot kits. Testing at baseline and every 6-12 months provides the most meaningful trend data.

Telomere length testing measures average telomere length in white blood cells, reported as a percentile relative to age-matched populations. Most directly relevant for epitalon users, but telomere attrition is a universal aging marker. Single timepoint measurements have limited utility — the value comes from tracking rate of change across multiple tests. qPCR-based consumer tests are affordable but have higher variability than the research-grade Flow-FISH method.

Inflammatory biomarkers are the most accessible and frequently actionable markers. High-sensitivity C-reactive protein (hsCRP) reflects systemic inflammation and is available through any standard lab panel. Interleukin-6 (IL-6) is a core SASP cytokine, making it directly relevant for those using FOXO4-DRI or other senolytic approaches. TNF-alpha provides additional resolution on inflammatory signaling. These markers respond on a shorter timescale than epigenetic clocks or telomere tests — meaningful shifts can appear within 8-12 weeks — making them useful for protocol adjustment.

NAD+ blood levels can be measured directly through specialized labs (whole blood NAD+ or NAD+/NADH ratio). Baseline testing before starting NMN, NR, or IV NAD+ protocols establishes whether repletion is actually needed. Retesting at 4-8 weeks confirms whether your chosen precursor and dose are reaching cellular targets.

The practical approach: test hsCRP and a metabolic panel quarterly. Add an epigenetic age test at baseline and annually. Add specialized markers (telomere length, NAD+ levels, IL-6) based on which peptides you are using. Your own longitudinal data is more informative than any population-level study for guiding protocol decisions.

Related Reading

• Longevity Peptides Overview — goal page covering all longevity-focused peptides
• Epitalon Benefits: 7 Anti-Aging Effects Ranked (2026) — deep dive on telomerase activation and beyond
• MOTS-c Benefits — metabolic aging and exercise mimetic effects
• NAD+ Benefits — sirtuin activation and metabolic support
• GHK-Cu Dosing Guide — protocols for injectable and topical use
• SS-31 Dosing Guide — elamipretide protocols and clinical context
• FOXO4-DRI Dosing Guide — senolytic cycling protocols
• Humanin Dosing Guide — neuroprotective dosing strategies

References

1. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278. PubMed

2. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PubMed

3. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261. PubMed

4. Siegel MP, Kruse SE, Percival JM, et al. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife. 2020;9:e55513. PubMed

5. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PubMed

6. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. PubMed

7. Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147. PubMed

8. Pickart L, Vasquez-Soltero JM, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PubMed